NCT07082595 Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study
| NCT ID | NCT07082595 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-07 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-07-07 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Parkinson's disease (PD) is a neurodegenerative disease that affects about 1% of the elderly population and accounts for substantial disability and health care costs. Disability is largely driven by mobility deficits caused by impaired gait. Effective treatments are available to restore lower limb function and improve gait, but response to treatment varies greatly from patient to patient and often shows only small effect sizes. Addressing this heterogeneity requires personalization, a concept referred to precision neurorehabilitation. StimuLOOP.PD-Sleep intends to foster structured and reproducible methods for precision neurorehabilitation of gait in PD. The investigators will conduct a proof-of-concept study to investigate a sleep intervention tailored to the individual patient in the context of motor rehabilitation. • Targeted auditory stimulation during sleep (TASS): The investigators aim to reactive rehabilitation-related memories through presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands. The investigators will leverage TASS to enhance consolidation of the movement patterns that are learned during rehabilitation. The investigators expect that this intervention will lead to greater gains in functional walking ability and balance. Beyond demonstrating a proof-of-concept for novel methods of applying TASS stimulation in the context of neurorehabilitation, positive results of this project may have implications for neurorehabilitation treatment in general by providing first insights into the benefits and interplay of TASS with a rehabilitation.
Eligibility Criteria
Inclusion Criteria: * Idiopathic Parkinson's disease with gait and postural stability deficits * ≥18 years of age * UPDRS III gait scores 1-3 * UPDRS III postural instability scores 1-3 * Prescribed rehabilitation therapy * Informed consent as documented by signature * Adjustments in dopaminergic medication and DBS stimulation to improve Exclusion Criteria: * Cognitive impairment, Montreal Cognitive Assessment (MoCa) \< 20 * Other neurological or medical condition that caused sustained clinically relevant gait and/or postural stability deficits * History of a physical or neurological condition that interferes with study procedures * Social and/or personal circumstances that interfere with the ability to return for assessments * Patients taking benzodiazepines or Z-drugs that have a significant effect on sleep EEG * Recent DBS implant (≤ 6 months) * Inability to perform outcome assessments without walking aid * Skin disorders/problems/allergies in face/ear area that could worsen with electrode application (e.g. nickel allergy)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07082595 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07082595 currently recruiting?
Yes, NCT07082595 is actively recruiting participants. Contact the research team at christian.baumann@usz.ch for enrollment information.
Where is the NCT07082595 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT07082595 clinical trial?
NCT07082595 is sponsored by University of Zurich. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.